Arsenic's 'Detox' Pathway Has a Catch: The Workers Who Finished It Had Higher Blood Pressure

I have always filed arsenic methylation under “good news.” You swallow a little inorganic arsenic in your well water, your liver grabs a methyl group and clamps it on, then clamps on another, and out the far end comes dimethylarsinic acid, DMA, which your kidneys flush. I learned it this way: methylation is how the body packs arsenic up and ships it out, and the efficient methylators, the people whose chemistry runs that assembly line fastest, were supposed to be the lucky ones.

Then a cross-sectional study published September 12 in Environmental Health stopped me cold, because in 393 young agricultural workers across El Salvador and Nicaragua, the men whose bodies most thoroughly finished that “detox” had systolic pressure as much as 7.24 mmHg higher than the men who left it half-done, not lower. The lucky ones weren’t lucky.

Here is what they measured. The team, led by Margaret Quaid and Madeleine Scammell at Boston University, looked at the share of each arsenic species in the men’s urine, and on average 11 percent came out as inorganic arsenic, 15 percent as monomethylated arsenic (MMA, the unfinished intermediate), and 74 percent as fully methylated DMA.

Then the blood pressure. Compared with the lower-DMA men, the higher-DMA men ran 3.75 mmHg higher on systolic pressure (95% CI 0.65 to 6.85) and 2.57 mmHg higher on pulse pressure. The men carrying more of the unfinished MMA went the other way, 3.70 mmHg lower. And when the researchers isolated the cleanest contrast, lots of DMA paired with little MMA, the gap opened to 7.24 mmHg of systolic pressure (95% CI 2.25 to 12.2). Seven points of systolic pressure across a whole population is the kind of shift that moves stroke and heart-attack counts.

Wait. Why would finishing the detox be worse than leaving it half-done? That is the question I could not put down, and the honest answer is that the “detox” label was probably wrong from the start.

Go to the mechanism and it clicks. The enzyme doing the methylating is AS3MT, and for years the assumption was that it neutralizes arsenic. Then someone ran the clean experiment in mice. In an apoE mouse model of atherosclerosis, animals engineered to lack As3mt were protected from arsenic-driven plaque, while the methylated arsenicals themselves, MMA and DMA, turned out to be just as artery-clogging as the raw inorganic stuff. Arsenobetaine, the harmless fish-derived form the enzyme never touches, did nothing. The authors wrote it plainly: “arsenic biotransformation is not necessarily a detoxification process but rather is required for its proatherogenic effects.” The methylation machinery pumps out reactive oxygen species and loads macrophages with lipid, and that is what drives the plaque. The step the textbook calls cleanup is the step that does the damage.

That is a mouse model of plaque, not blood pressure in Salvadoran cane cutters, so I am reading it as mechanism and not proof. But it lines up unnervingly well with what the human data just showed. In these men, the ones who finished the conversion had the higher pressure, and the mouse work says the finishing is exactly what turns arsenic into an artery problem. It also reframes the whole genetics-of-arsenic literature, where AS3MT variants have long been sorted into “protective” and “not.” If the enzyme is part of the weapon, “efficient” was never the safe bet.

Hold onto who these 393 men actually are, because this is not a toxicology puzzle on a whiteboard. They are cane cutters, brickmakers, corn and plantain farmers in the MesoAmerican Nephropathy Occupational Study, most of them under 35, and they sit at the front line of one of the strangest epidemics in the hemisphere. Across Central America, young manual laborers are dying of chronic kidney disease that fits none of the usual boxes, not diabetes, not obesity, not old age. At baseline, 7.4 percent of this cohort already had chronic kidney disease, and in the hardest-hit regions men die of it at 60 to 70 per 100,000. Strong young workers, kidneys quitting decades early.

What are they up against? Heat, punishing dehydration, agrochemicals, and a water supply carrying metals. Arsenic runs through the groundwater of El Salvador and the municipal water of Nicaragua, and this same cohort has already produced evidence that urinary glyphosate tracks with worsening kidney-injury markers and falling filtration. The median total urinary arsenic here was about 11 µg/L. That is not a catastrophic industrial dose. It is the moderate, background-contamination range that millions of people live in, and only men above 5 µg/L of urinary arsenic even qualified for this analysis, so this is what “a little arsenic” does, not “a lot.” Plenty of Americans sit in that same range on private wells the federal government does not regulate and does not test; under the Safe Drinking Water Act that testing is the owner’s problem, nobody else’s.

Be clear about what a snapshot like this can carry. It is cross-sectional, blood pressure and arsenic caught at one moment, so no one can say the methylation pattern came first and the pressure followed. Known hypertension was an exclusion criterion and the sample is small, both of which would tend to shrink the measured effect rather than inflate it. This is a strong, mechanistically backed signal, not a verdict, and it points hard at the longitudinal study nobody has funded.

Credit where it belongs: this was paid for by the public, through an NIEHS grant, on a population with no commercial constituency and no influencer working the angle. The authors declared no competing interests. This is the unglamorous environmental research that actually protects working people, and it is the first thing cut when budgets tighten and the affected are poor farmhands in someone else’s country. The comfortable “your body detoxes it” story asked nothing of regulators. This data asks a great deal.

So here is my conclusion. I am not going to lean on the old reassurance that efficient methylation keeps me safe, because the biology under it just gave way. If I lived on well water, I would test it for arsenic this year, and I would not wait for a guideline to tell me that 11 µg/L is worth worrying about.

Sources

1. Environmental Health – Quaid et al., “The Association of Arsenic Metabolism and Blood Pressure: A Cross-Sectional Analysis in MANOS” (2026), full text via PMC
2. Toxicological Sciences – methylated arsenicals and As3mt-mediated methylation promote atherosclerosis in the apoE−/− mouse model
3. Kidney International Reports – high prevalence of chronic kidney disease of unknown etiology in the MANOS cohort (baseline)
4. ISEE 2024 – urinary glyphosate predicts kidney-injury biomarkers and eGFR change in MANOS
5. PubMed record for the MANOS arsenic-metabolism and blood-pressure analysis (2026)
6. U.S. EPA – private drinking water wells are not regulated under the Safe Drinking Water Act; owners are responsible for testing